Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Inhibrx Q2 EPS $(0.55) Up From $(0.99) YoY

Inhibrx (NASDAQ:INBX) reported quarterly losses of $(0.55) per share. This is a 44.44 percent increase over losses of $(0.99) per share from the same period last year.
byBenzinga Newsdesk
August 9, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Inhibrx (NASDAQ:INBX) reported quarterly losses of $(0.55) per share. This is a 44.44 percent increase over losses of $(0.99) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Return On Capital Employed Overview: Tesla

By Benzinga Insights
Today, 4:07 AM
Looking at Q2, Tesla (NASDAQ:TSLA) earned $1.31 billion, a 120.88% increase from the preceding quarter. Tesla also posted a total of $11.96 billion in sales, a 15.1% increase since Q1. In Q1, Tesla earned $594.00 million, and total sales reached $10.39 billion.

TSLA

Read More

Karyopharm Therapeutics Earnings Preview

By Benzinga Insights
Today, 4:07 AM
Karyopharm Therapeutics (NASDAQ:KPTI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Karyopharm Therapeutics will report an earnings per share (EPS) of $-0.63.

KPTI